Stereotactic body radiation therapy for prostate cancer: a study comparing 3-year genitourinary toxicity between CyberKnife and volumetric-modulated arc therapy by propensity score analysis

Table 3 Univariate and multivariate analyses of the peak values in acute phase of IPSS

Explanatory variable	Single regression				Multiple regression
Explanatory variable	Parameter estimates	Standard error	95% CI	p Value	Parameter estimates	Standard error	p Value
Age (years)	0.38	0.14	0.1–0.67	0.01	0.35	0.13	0.01
Risk group	−2.06	1.43	−4.92–0.8	0.16
Neoadjuvant ADT	−6.01	3.15	−12.2–0.28	0.06	−5.88	2.85	0.04
Antithrombotic therapy	0.34	2.49	−4.63–5.3	0.89
Diabetes	−5.8	2.62	−11.0–0.6	0.03	−4.25	2.36	0.08
Medication to improve dysuria at baseline	5.05	2.18	0.7–9.4	0.023	4.43	2.01	0.03
Treatment modality	4.0	1.75	0.52–7.48	0.024	3.63	1.60	0.03
Larger PTV volume (> 49.5 cc)	5.09	1.70	1.69–8.48	0.004	1.99	1.74	0.25
Bladder volume (cc)	−3.03	6.34	−15.7–9.6	0.63
Bladder Dmean (Gy)	0.44	0.44	−0.44–1.32	0.32
Urethra Dmean (Gy)	225.6	123.1	−19.9–471.2	0.07	−13.9	282.0	0.96
Urethra Dmax (Gy)	1.42	2.11	−2.78–5.62	0.50

IPSS International Prostate Symptom Score; CI confidence interval; ADT androgen deprivation therapy; PTV planning target volume; Dmean mean dose; Dmax maximum dose

ISSN: 1748-717X